{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=23",
    "query": {
      "condition": "Recurrent",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 9639,
    "total_pages": 964,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T22:47:34.286Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00222703",
      "title": "Enhancing Tobacco Abstinence Following Hospitalization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hospitalized Smokers",
        "Chronic Diseases",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "Smoking relapse prevention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2002-05",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2005-09-22",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00222703"
    },
    {
      "nct_id": "NCT06312670",
      "title": "Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
        "Prostate Cancer",
        "Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "EPI-7386",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Androgen Deprivation Therapy (ADT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pedro Barata, MD, MSc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2024-05-16",
      "completion_date": "2025-01-09",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06312670"
    },
    {
      "nct_id": "NCT02197169",
      "title": "DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma or Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Single intratumoral injection of DNX-2401",
          "type": "DRUG"
        },
        {
          "name": "Interferon-gamma",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DNAtrix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-09-11",
      "completion_date": "2018-03-15",
      "has_results": false,
      "last_update_posted_date": "2018-07-16",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197169"
    },
    {
      "nct_id": "NCT04751383",
      "title": "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Risk Neuroblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma",
        "Refractory Neuroblastoma",
        "Resectable Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dinutuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Magrolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "2 Years to 35 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-08-31",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04751383"
    },
    {
      "nct_id": "NCT05453851",
      "title": "A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Benign Pancreatic Neoplasm",
        "Chronic Pancreatitis",
        "Recurrent Acute Pancreatitis"
      ],
      "interventions": [
        {
          "name": "Pancreatectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Treatment Planning",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2026-07-01",
      "completion_date": "2030-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05453851"
    },
    {
      "nct_id": "NCT00022451",
      "title": "Tipifarnib in Treating Young Patients With Refractory Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-06",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 56,
      "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 46 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022451"
    },
    {
      "nct_id": "NCT07759102",
      "title": "Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Defined Hematopoietic Stem Cells/Immune Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-09-01",
      "completion_date": "2033-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07759102"
    },
    {
      "nct_id": "NCT02767921",
      "title": "sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infiltrating Bladder Urothelial Carcinoma",
        "Recurrent Bladder Carcinoma",
        "Stage I Prostate Cancer",
        "Stage I Renal Cell Cancer",
        "Stage II Bladder Urothelial Carcinoma",
        "Stage II Renal Cell Cancer",
        "Stage IIA Prostate Cancer",
        "Stage IIB Prostate Cancer",
        "Stage III Prostate Cancer",
        "Stage III Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Radical Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Recombinant EphB4-HSA Fusion Protein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-08-02",
      "completion_date": "2021-11-15",
      "has_results": false,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02767921"
    },
    {
      "nct_id": "NCT00014547",
      "title": "BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BBR 3464",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theradex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-07-24",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 18,
      "location_summary": "Hoover, Alabama • Fayetteville, Arkansas • Berkeley, California + 15 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Southington",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014547"
    },
    {
      "nct_id": "NCT05116540",
      "title": "Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "HB-adMSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hope Biosciences Research Foundation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-11-24",
      "completion_date": "2024-06-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-10-17T22:47:34.286Z",
      "location_count": 1,
      "location_summary": "Sugar Land, Texas",
      "locations": [
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05116540"
    }
  ]
}